Ara 290 vs Sermorelin
Extensively Studied vs Well Studied
synergistic Mechanism-based · 47% Ara 290 and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ara 290 Sermorelin
Weight 1,257 Da 3,358 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) 10-12 minutes
Chain 11 amino acids 29 amino acids
Type Engineered peptide GHRH analog
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Ara 290 Sermorelin
Status Extensively Studied Well Studied
References 5 studies 5 studies
Latest 2024 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.